Maltase-glucoamylase inhibition potency and cytotoxicity of pyrimidine-fused compounds: An in silico and in vitro approach

Computational Exploration of Phenolic Compounds from Endophytic Fungi as α-Glucosidase Inhibitors for Diabetes Management

Diabetes has become a global epidemic, affecting even the younger people on an alarming scale. Inhibiting intestinal α-glucosidase is one of the key approaches to managing type 2 diabetes (T2D). In the present study, phenolic compounds (PCs) produced by endophytic fungi as potential α-glucosidase inhibitors (AGIs) are explored through ADMET profiling, molecular docking, and molecular dynamics (MD) Simulations. After 150 PCs were screened for their drug-likeness and toxicity properties, 45 molecules were selected. These were subjected to molecular docking studies against human N-terminal maltase-glucoamylase (NtMGAM). Based on binding energy and IC50 values, the best five PCs from different chemical classes (depsidones, phenolic acids, butenolides, furanones, and polyketides) were studied for their binding dynamics with NtMGAM employing all-atom MD simulations. Among the five ligands analyzed, the methybutyrolactone III (BUT)-NtMGAM complex exhibited significantly higher active site flexibility, indicating a conformational change in response to ligand binding. BUT interacted specifically with both key residues, Asp443 and Phe575, critical for enzyme-inhibitor stability. These interactions, coupled with increased flexibility, suggest enhanced stabilization of BUT in the active site pocket. BUT also exhibited one of the most favorable toxicity profiles among molecules analyzed using ProTox 3.0. Molecular mechanics Poisson-Boltzmann surface area calculations confirmed that BUT had the highest binding energy (-35.01 kcal/mol) driven by substantial van der Waals and electrostatic interactions. Another butenolide derivative, aspernolide (ALD) ranked second in the binding energy score (-31.13 kcal/mol). These findings suggest that PCs possessing butenolide scaffolds, like BUT and ALD, hold great promise as potential AGIs for managing T2D. These findings, however, need to be further validated through in vivo experimentation.

Deciphering Molecular Aspects of Potential α-Glucosidase Inhibitors within Aspergillus terreus: A Computational Odyssey of Molecular Docking-Coupled Dynamics Simulations and Pharmacokinetic Profiling

Hyperglycemia, as a hallmark of the metabolic malady diabetes mellitus, has been an overwhelming healthcare burden owing to its high rates of comorbidity and mortality, as well as prospective complications affecting different body organs. Available therapeutic agents, with α-glucosidase inhibitors as one of their cornerstone arsenal, control stages of broad glycemia while showing definitive characteristics related to their low clinical efficiency and off-target complications. This has propelled the academia and industrial section into discovering novel and safer candidates. Herein, we provided a thorough computational exploration of identifying candidates from the marine-derived Aspergillus terreus isolates. Combined structural- and ligand-based approaches using a chemical library of 275 metabolites were adopted for pinpointing promising α-glucosidase inhibitors, as well as providing guiding insights for further lead optimization and development. Structure-based virtual screening through escalating precision molecular docking protocol at the α-glucosidase canonical pocket identified 11 promising top-docked hits, with several being superior to the market drug reference, acarbose. Comprehensive ligand-based investigations of these hits' pharmacokinetics ADME profiles, physiochemical characterizations, and obedience to the gold standard Lipinski's rule of five, as well as toxicity and mutagenicity profiling, proceeded. Under explicit conditions, a molecular dynamics simulation identified the top-stable metabolites: butyrolactone VI (SK-44), aspulvinone E (SK-55), butyrolactone I 4''''-sulfate (SK-72), and terrelumamide B (SK-173). They depicted the highest free binding energies and steadiest thermodynamic behavior. Moreover, great structural insights have been revealed, including the advent of an aromatic scaffold-based interaction for ligand-target complex stability. The significance of introducing balanced hydrophobic/polar moieties, like triazole and other bioisosteres of carboxylic acid, has been highlighted across docking, ADME/Tox profiling, and molecular dynamics studies for maximizing binding interactions while assuring safety and optimal pharmacokinetics for targeting the intestinal-localized α-glucosidase enzyme. Overall, this study provided valuable starting points for developing new α-glucosidase inhibitors based on nature-derived unique scaffolds, as well as guidance for prospective lead optimization and development within future pre-clinical and clinical investigations.